Menten AI

Executive Summary

Menten AI is a Stockholm-based biotechnology company leveraging generative AI to design novel peptide macrocycle therapeutics, addressing targets challenging for traditional small molecules and biologics. Its proprietary platform, MAUD 1.0, integrates AI with physics-based modeling to accelerate preclinical discovery. Founded in 2020, the company operates in the pre-clinical stage and has attracted partnerships with major pharmaceutical firms, underscoring its potential to revolutionize drug design for undruggable targets. Menten AI's approach offers advantages in specificity, stability, and synthetic accessibility, positioning it as a key player in the AI-driven drug discovery space. Looking ahead, Menten AI is poised to advance its platform and expand collaborations. Upcoming milestones include the release of MAUD 2.0, which could enhance predictive accuracy and broaden therapeutic scope, and potential new partnership announcements with pharma giants seeking macrocycle solutions. The company may also pursue Series A funding to support internal pipelines and platform development. With a strong scientific foundation and growing industry interest, Menten AI represents a high-potential investment opportunity in the convergence of AI and peptide therapeutics.

Upcoming Catalysts (preview)

• Q3 2026New Pharma Partnership Announcement75% success
• Q4 2026Release of MAUD 2.0 Platform60% success
• Q2 2026Series A Funding Round Closing80% success